戻る Agenda
Pharma, Academia and CRO Preferred Partnerships: Why Collaboration Makes a Better Global Trial
Session Chair(s)
Mary Ann Sellers, MSN
Senior Project Leader
Duke Clinical Research Institute, United States
This session will describe successful strategies used by a multi-partner collaboration to manage challenges encountered in an ongoing “megatrial.” The team will share structural and operational models that have been used to drive novel solutions.
Learning Objective : Describe the advantages of an integrated partnership that includes pharma, AROs and CROs; Describe the challenges/potential solutions encountered in a global collaboration; Identify actions to capitalize on each group’s strengths to ensure a strong partnership that results in successful trial execution.
Speaker(s)
Why Collaboration Makes a Better Global Trial: An Academic Perspective
Michelle Masterson
Oxford University, United Kingdom
Project Manager, Diabetes Trials Unit
Why Collaboration Makes a Better Global Trial: A Sponsor Perspective
Joe Zimmerman, MBA
Spectrum Pharmaceuticals, Inc., United States
Vice President, Clinical Operations
Why Collaboration Makes a Better Global Trial: A CRO Perspective
Sara Tullberg, PHD
PAREXEL International, United Kingdom
Senior Project Leader